AZ-WORLD-VIEW
31.3.2022 17:02:13 CEST | Business Wire | Press release
World View , the leading stratospheric ballooning and space tourism company, today announced environmentalist, actor, and UN Environment Goodwill Ambassador Adrian Grenier has been named its Chief Earth Advocate. In this new role he will support World View’s mission to rediscover Earth, inspiring new perspectives on the planet and encouraging deeper respect for it as a living organism. Today’s announcement follows the company’s entry into the space tourism and exploration market offering an affordable, long duration and accessible space experience on Earth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220331005341/en/
World View designed its space tourism experience based on the company’s business purpose: World View exists to inspire, create, and explore new perspectives for a radically improved future. The company believes its space tourism experience provides customers with an “awe inspiring” journey, from the time spent at one of World View’s spaceports to the time spent at the edge of space. World View is on a mission to deliver this transformative moment to a critical mass of humans knowing that it could lead to a markedly improved future for our fragile planet.
In his new role, Grenier will collaborate with World View’s leadership to ideate and develop strategies to ensure the company's sustainability goals are met through global partnerships, programming, and initiatives. He will also contribute to the development of its environmental strategy while playing a key role in helping participants understand their individual relationship to the planet as they prepare for and reflect on their trip.
"Adrian’s history as an eco-activist speaks for itself. World View is happy to welcome Adrian as our Chief Earth Advocate. Our main goal is to enable customers to see the beauty of the Earth we inhabit so we can radically improve the future of our own planet. Adrian is an excellent advocate and will help us in our mission,” said Ryan Hartman, President and CEO of World View.
Conservation has long been at the heart of Grenier’s social activism. In 2017, he helped the UN Environment Programme launch Clean Seas, a campaign to end marine plastic pollution. He also supported Wild for Life, advocating for the conservation of sawfish. The Lonely Whale Foundation, which he co-founded, strives to inspire empathy towards marine species and develop lifelong advocates for ocean health. Its innovative StopSucking campaign aims to discourage the use of single-use plastic straws, which are particularly harmful to marine wildlife. Grenier actively supports organizations focused on habit-changing education.
“I am honored to serve as World View’s Chief Earth Advocate. The partnership allows me to use my platform to champion healthier, regenerative choices for the Earth. Space tourism is an exciting concept, and the fact that World View puts our interconnectedness squarely at the heart of exploration is in line with my personal values. Together, we will be able to honor the planet and encourage future generations to be better stewards of its resources and beauty,” said Adrian Grenier, Chief Earth Advocate of World View.
World View Mission: Rediscover Earth
World View’s global space tourism program will begin its first commercial flights in early 2024. Unlike any other space tourism company, World View plans to have flights depart from state-of-the-art spaceports located in iconic locations like the Grand Canyon and Great Barrier Reef, providing participants the opportunity to experience natural and man-made wonders from the ground and the edge of space.
Flights will lift eight participants and two World View crew members in a zero-pressure stratospheric balloon and pressurized space capsule to 100,000 feet altitude, nearly 23 miles into the stratosphere, for a life-changing experience that will last six to 12 hours with average flight duration between six and eight hours. Participants will lift off before dawn to watch the sunrise over Earth, view the curvature of our planet and experience the darkness of space. They will see a world without borders, without race and will fully experience and immerse themselves in the beauty, fragility, history, and importance of the areas surrounding each location and of the Earth itself.
ABOUT WORLD VIEW
World View is the leading stratospheric exploration company on a mission to inspire the global community to rediscover Earth. Through both its legacy Stratollite imaging and newly launched space tourism and exploration businesses, World View is working to ensure its ultimate objective: honor the planet so that future generations will feel blessed to call it home. For more information, visit worldview.space .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005341/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom